[Hepatocellular carcinoma following interferon therapy]

Area of Science:

• Hepatology
• Oncology
• Virology

Background:

• Hepatocellular carcinoma (HCC) is a significant global health concern.
• Interferon (IFN) therapy has been used in managing Hepatitis C virus (HCV) infections, a primary risk factor for HCC.
• Understanding the relationship between IFN therapy, HCV clearance, and HCC development is crucial for patient management.

Purpose of the Study:

• To evaluate the outcomes of patients with resected hepatocellular carcinoma (HCC) following interferon (IFN) therapy.
• To investigate the correlation between HCV-RNA status, liver histology, and HCC development post-IFN treatment.
• To assess the need for continued patient surveillance during and after IFN therapy for HCC.

Main Methods:

• Retrospective analysis of six patients with resected HCC after IFN therapy.
• Hepatitis C virus RNA (HCV-RNA) detection using polymerase chain reaction (PCR) before and after IFN treatment.
• Histopathological examination of liver biopsies to assess pre-existing liver disease (pre-cirrhosis, chronic active hepatitis 2B [CAH2B]) and post-treatment changes (cirrhosis, CAH2B).

Main Results:

• All six patients were positive for HCV-RNA before IFN therapy.
• HCV-RNA became negative in two patients post-IFN, but re-positive at HCC detection.
• Histological analysis revealed pre-cirrhosis in four patients and CAH2B in one prior to IFN; post-treatment, five developed cirrhosis and one had CAH2B in non-cancerous liver tissue. No significant correlation was found between HCC detection interval, tumor size, location, and histological findings.

Conclusions:

• Hepatocellular carcinoma (HCC) can develop in patients treated with interferon (IFN) even after achieving viral clearance.
• Close monitoring of patients undergoing or completing IFN therapy for Hepatitis C virus (HCV) is essential.
• Regular follow-up using serum alpha-fetoprotein levels and liver ultrasonography is recommended for early HCC detection.